Correlation Between Milestone Pharmaceuticals and Unicycive Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Milestone Pharmaceuticals and Unicycive Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Milestone Pharmaceuticals and Unicycive Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Milestone Pharmaceuticals and Unicycive Therapeutics, you can compare the effects of market volatilities on Milestone Pharmaceuticals and Unicycive Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Milestone Pharmaceuticals with a short position of Unicycive Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Milestone Pharmaceuticals and Unicycive Therapeutics.

Diversification Opportunities for Milestone Pharmaceuticals and Unicycive Therapeutics

0.66
  Correlation Coefficient

Poor diversification

The 3 months correlation between Milestone and Unicycive is 0.66. Overlapping area represents the amount of risk that can be diversified away by holding Milestone Pharmaceuticals and Unicycive Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Unicycive Therapeutics and Milestone Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Milestone Pharmaceuticals are associated (or correlated) with Unicycive Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Unicycive Therapeutics has no effect on the direction of Milestone Pharmaceuticals i.e., Milestone Pharmaceuticals and Unicycive Therapeutics go up and down completely randomly.

Pair Corralation between Milestone Pharmaceuticals and Unicycive Therapeutics

Given the investment horizon of 90 days Milestone Pharmaceuticals is expected to generate 1.3 times less return on investment than Unicycive Therapeutics. But when comparing it to its historical volatility, Milestone Pharmaceuticals is 1.55 times less risky than Unicycive Therapeutics. It trades about 0.28 of its potential returns per unit of risk. Unicycive Therapeutics is currently generating about 0.24 of returns per unit of risk over similar time horizon. If you would invest  50.00  in Unicycive Therapeutics on August 29, 2024 and sell it today you would earn a total of  18.00  from holding Unicycive Therapeutics or generate 36.0% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Milestone Pharmaceuticals  vs.  Unicycive Therapeutics

 Performance 
       Timeline  
Milestone Pharmaceuticals 

Risk-Adjusted Performance

12 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Milestone Pharmaceuticals are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unsteady basic indicators, Milestone Pharmaceuticals unveiled solid returns over the last few months and may actually be approaching a breakup point.
Unicycive Therapeutics 

Risk-Adjusted Performance

17 of 100

 
Weak
 
Strong
Solid
Compared to the overall equity markets, risk-adjusted returns on investments in Unicycive Therapeutics are ranked lower than 17 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak fundamental indicators, Unicycive Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

Milestone Pharmaceuticals and Unicycive Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Milestone Pharmaceuticals and Unicycive Therapeutics

The main advantage of trading using opposite Milestone Pharmaceuticals and Unicycive Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Milestone Pharmaceuticals position performs unexpectedly, Unicycive Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Unicycive Therapeutics will offset losses from the drop in Unicycive Therapeutics' long position.
The idea behind Milestone Pharmaceuticals and Unicycive Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.

Other Complementary Tools

Content Syndication
Quickly integrate customizable finance content to your own investment portal
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital